1. Pink Sheet
  2. >>Market Access
  3. >>Pricing Debate

Medicare IPI Model Could Import Benefit Of Biosimilar Competition, Azar Suggests

 
• By Cathy Kelly

HHS secretary notes Medicare Part B International Pricing Index could ‘harness’ biosimilar price competition seen abroad for US market, where follow-ons have not been able to significantly impact pricing.

Road sign tells of a big sale - Image

The proposed Medicare Part B International Pricing Index model could help bring the price-lowering impact of biosimilar competition to the US even though follow-ons have not made significant inroads here, HHS Secretary Alex Azar suggested at a health care policy conference in Washington DC Jan. 15.

“The IPI model is not just a way to leverage the competition and negotiation done abroad, it is also a way to accomplish one of the goals … we all share: harnessing biosimilar competition,” he told the event, sponsored by the the Partnership for Employer-Sponsored Coverage and the Council for

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Pricing Debate

HHS Negotiating With Manufacturers On Most Favored Nation Drug Pricing

 
• By Cathy Kelly

MFN policy would would apply to all single source drugs in all insurance markets, according to HHS release. Secretary Robert F. Kennedy Jr. said the department is discussing the plan with drug sponsors.

‘Tectonic’ Arkansas PBM Legislation May Upend Industry

 
• By Tim Casey

Industry will fight hard to prevent other states or the federal government from adopting measures similar to Arkansas' law preventing PBMs from owning pharmacies.

Will International Prices Influence Medicare Price Negotiation?

 
• By Cathy Kelly

A former CMS official suggested the most likely way it could happen is through a Center for Medicare and Medicaid Innovation demonstration.

Industry Leaders Grapple With Trump’s Most Favored Nation Pricing Plan

 
• By Jessica Merrill

At the Bank of America health care conference, pharma leaders speculated on the impact of Trump’s most favored nation pricing executive order on US and European markets.

More from Market Access

Will International Prices Influence Medicare Price Negotiation?

 
• By Cathy Kelly

A former CMS official suggested the most likely way it could happen is through a Center for Medicare and Medicaid Innovation demonstration.

Managed Access Agreement Fails To Help BioMarin’s Brineura Secure Routine Reimbursement In England

 
• By Francesca Bruce

BioMarin’s ultra-rare disease drug Brineura has breached cost-effectiveness thresholds for highly specialized treatments in England and looks set to be denied routine funding on the National Health Service.

Industry Leaders Grapple With Trump’s Most Favored Nation Pricing Plan

 
• By Jessica Merrill

At the Bank of America health care conference, pharma leaders speculated on the impact of Trump’s most favored nation pricing executive order on US and European markets.